Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation (MITRA-FR)
Source: View publication →
The MITRA-FR trial demonstrated that in patients with severe symptomatic secondary mitral regurgitation and heart failure, the addition of transcatheter mitral valve repair using the MitraClip system to guideline-directed medical therapy did not reduce the rate of death or unplanned hospitalization for heart failure at 12 months.
Key Findings
Study Design
Study Limitations
Clinical Significance
MITRA-FR suggests that routine percutaneous mitral valve repair for secondary mitral regurgitation in patients with advanced systolic heart failure is not superior to optimized medical therapy alone in improving clinical outcomes. This underscores the importance of patient selection, specifically identifying phenotypes where the valvular regurgitation is disproportionate to the degree of left ventricular dilation.
Historical Context
The MITRA-FR trial was conducted to provide high-level evidence for transcatheter mitral valve repair in secondary mitral regurgitation, an area previously supported only by non-randomized studies. Its results were released shortly before the similarly designed but result-divergent COAPT trial; the contrast between the neutral MITRA-FR findings and the positive COAPT results led to significant debate regarding the underlying patient phenotypes and the necessity of optimized medical therapy prior to intervention.
Guided Discussion
High-yield insights from every perspective
In the context of the MITRA-FR trial, what is the underlying pathophysiology of secondary (functional) mitral regurgitation, and why was it hypothesized that a mechanical intervention like MitraClip would improve heart failure outcomes?
Key Response
Secondary MR results from left ventricular (LV) remodeling, dilation, and dysfunction, which leads to apical and lateral displacement of the papillary muscles, causing tethering of the leaflets. The hypothesis was that reducing the volume overload caused by MR would break the 'MR-begets-MR' cycle of LV dilation, thereby reducing symptoms and slowing the progression of heart failure.
Despite a high technical success rate in the MITRA-FR trial, there was no significant difference in clinical outcomes. How does this finding influence the selection of patients for percutaneous edge-to-edge repair (TEER) versus prioritizing further titration of guideline-directed medical therapy (GDMT)?
Key Response
MITRA-FR demonstrated that for patients with secondary MR, simply fixing the valve does not improve outcomes if the underlying LV cardiomyopathy is the primary driver. It emphasizes that TEER should not be a substitute for GDMT. In clinical practice, TEER is reserved for those who remain symptomatic despite maximally tolerated GDMT (including CRT if indicated) and fit specific anatomical/phenotypic criteria identified in later trials like COAPT.
Compare the 'proportionate' versus 'disproportionate' mitral regurgitation phenotypes as they relate to the MITRA-FR and COAPT results. Why did MITRA-FR potentially fail to show a benefit based on these echocardiographic parameters?
Key Response
In MITRA-FR, the MR was 'proportionate' to the LV dilation (larger LV volumes, smaller Effective Regurgitant Orifice Area [EROA] around 0.31 cm²). In COAPT, the MR was 'disproportionate' (smaller LV volumes, larger EROA around 0.41 cm²). MITRA-FR suggested that when MR is just a marker of advanced LV failure, mechanical repair is less effective than when the MR is disproportionately severe relative to the degree of LV dilation.
MITRA-FR reported a 12-month mortality rate of approximately 24% in both groups. What does this high event rate tell us about the patient population studied, and how does it challenge the integration of TEER into the management of advanced heart failure?
Key Response
The high mortality rate indicates that the MITRA-FR population had very advanced heart failure where the prognosis is dominated by the underlying cardiomyopathy. For the attending, the teaching point is that MitraClip is not a 'salvage' procedure for end-stage LV failure; rather, it is most effective in a specific window where the valve pathology is a significant contributor to the hemodynamic burden, but the ventricle is still viable enough to benefit from afterload reduction.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
From a trial design perspective, how did the lack of a standardized 'run-in' period for medical therapy optimization in MITRA-FR introduce potential confounding compared to the rigorous GDMT stabilization required in the COAPT trial?
Key Response
MITRA-FR reflected 'real-world' practice where patients were enrolled while medical therapy was still being adjusted. This introduces variability; some patients might have improved on GDMT alone regardless of the MitraClip. COAPT’s requirement for centralized oversight of GDMT prior to enrollment ensured that the treatment effect of the device was isolated from the benefits of optimized medication, which is a critical methodological difference in internal validity.
If MITRA-FR were submitted today, how would you evaluate the 12-month primary endpoint duration given that LV remodeling and mortality benefits in heart failure trials often require longer follow-up to reach statistical significance?
Key Response
A tough reviewer would flag that 12 months might be insufficient to capture the long-term benefits of a structural intervention on mortality. Indeed, the 2-year and 5-year data from related trials show diverging curves. Editors must weigh the value of early reporting against the risk of a 'false negative' (Type II error) resulting from a follow-up period that is shorter than the natural history of the disease process.
How do the results of MITRA-FR reconcile with the 2020 ACC/AHA Valve Guidelines which give TEER a Class 2a recommendation for secondary MR? What specific thresholds must be met for this evidence to apply?
Key Response
The guidelines incorporate MITRA-FR as a cautionary tale, limiting the Class 2a recommendation to a 'COAPT-like' population: EROA ≥0.40 cm², LV end-systolic diameter ≤7.0 cm, and continued symptoms despite maximally tolerated GDMT. MITRA-FR helps define the 'lower boundary' of benefit, ensuring that TEER is not over-utilized in patients with excessively dilated ventricles or less-than-severe MR (EROA <0.30 cm²).
Clinical Landscape
Noteworthy Related Trials
EVEREST II Trial
Tested
Percutaneous mitral-valve repair with MitraClip
Population
Patients with moderate-to-severe or severe mitral regurgitation
Comparator
Conventional mitral-valve surgery
Endpoint
Composite of death, surgery for mitral-valve dysfunction, or 3+/4+ mitral regurgitation
COAPT Trial
Tested
Transcatheter edge-to-edge repair (TEER) with MitraClip
Population
Patients with symptomatic heart failure and moderate-to-severe secondary mitral regurgitation
Comparator
Guideline-directed medical therapy alone
Endpoint
All hospitalizations for heart failure within 24 months
RESHAPE-HF2 Trial
Tested
Transcatheter edge-to-edge repair (TEER)
Population
Patients with symptomatic heart failure and moderate-to-severe or severe secondary mitral regurgitation
Comparator
Guideline-directed medical therapy
Endpoint
Composite of cardiovascular death or heart failure hospitalizations
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis